Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiqi Shengjin powder is a traditional Chinese medicine (TCM) herbal formulation used primarily for the treatment of conditions associated with Qi and Yin deficiency syndromes. It is being investigated for its efficacy and safety in patients with abnormal glucose metabolism (including impaired fasting glucose, abnormal glucose tolerance, or type 2 diabetes mellitus) and grade 1-2 essential hypertension[1][4][6]. The mechanism of action is not fully elucidated but may involve modulation of oxidative stress, lipid metabolism, vascular injury markers, and improvement in TCM syndrome integration. Clinical trials are ongoing to assess its impact on blood pressure control as well as secondary outcomes such as oxidative stress index, lipid metabolism index, ambulatory blood pressure monitoring indices, glucose metabolism indices, vascular injury detection indices, aging indicators[1]. The formula is developed within the framework of TCM by institutions such as Beijing Hospital of Traditional Chinese Medicine affiliated with Capital Medical University[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiqi Shengjin powder.